Exhaled-breath glucose monitoring

01Overview and value chain#

Markers EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)

Exhaled-breath glucose monitoring aims to track diabetes-relevant metabolic state from a breath sample instead of a fingerstick blood test or implanted continuous glucose monitor. The commercially furthest-along devices in this category actually detect breath acetone or ketones — metabolic byproducts correlated with fat metabolism and, in diabetes management, with risk of diabetic ketoacidosis — rather than glucose molecules themselves; PranaQ, Invoy Technologies and LEVL all build breath acetone/ketone sensing devices marketed into metabolic-health and diabetes-adjacent use cases. Invoy Technologies holds patents covering its breath analysis device and wearable breath-analyte measurement hardware, and runs an active ketone research device program for breath acetone studies. LEVL’s breath ketone analyzer targets fat-metabolism tracking. A newer entrant, PREEVNT, is pursuing a more direct blood-glucose claim with its ISAAC device, which debuted as a non-invasive blood glucose alert device at the CES Digital Health exhibit and is publicly documenting its path through FDA review.

The key directions of exhaled-breath glucose monitoring are:

1. Breath acetone/ketone sensing (Breath Acetone Ketone Sensing): electrochemical or semiconductor gas sensors detecting breath acetone as a proxy for fat metabolism and diabetes-relevant ketosis — PranaQ, Invoy Technologies, LEVL.
2. Direct breath glucose alert devices (Breath Glucose Alert Devices): devices claiming to alert on blood-glucose status directly from a breath sample rather than via a ketone proxy — PREEVNT’s ISAAC.
3. Wearable breath analyte measurement (Wearable Breath Analyte Measurement): patented wearable form factors for continuous or repeated breath-analyte sampling outside a single handheld reading — Invoy Technologies.
4. FDA clearance pathway navigation (FDA Clearance Pathway): the regulatory-validation journey each device must complete before its glucose or ketone claim can be marketed as a medical diagnostic — publicly documented by PREEVNT for ISAAC.

Sectoral value chain#

[breath sample collection] ──> [gas sensor detection (acetone/VOC)] ──> [signal processing & blood-reference calibration]
                                                    │
                                       (alert/reading generation)
                                                    │
                                                    ▼
[diabetes management integration] <─── [regulatory clearance (FDA)] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Electrochemical/semiconductor gas sensing (Breath Acetone Ketone Sensing): solid-state gas sensors tuned to detect breath acetone at parts-per-billion concentrations, the core chemistry behind PranaQ, Invoy Technologies and LEVL’s devices.
• Direct glucose-correlate detection (Breath Glucose Alert Devices): sensor approaches aiming to correlate breath signal more directly with blood glucose rather than the acetone/ketone intermediate, PREEVNT’s stated technical direction for ISAAC.
• Wearable continuous breath sampling (Wearable Breath Analyte Measurement): patented wearable hardware (Invoy Technologies) extends breath analysis from a single spot-check reading toward more continuous monitoring.

02US#

The US hosts every source-confirmed company in this category, spanning established breath-ketone sensing and a newer direct-glucose entrant.

PranaQ, Invoy, LEVL, PREEVNT, FDA#

• PranaQ: builds a breath acetone sensing device targeted at metabolic-health and diabetes-adjacent monitoring use cases.
• Invoy Technologies: holds patents covering its breath analysis device and wearable breath-analyte measurement hardware, and runs an active ketone research device program for breath acetone studies.
• LEVL: its breath ketone analyzer targets fat-metabolism tracking, adjacent to but distinct from a direct diabetes-glucose claim.
• PREEVNT: its ISAAC device debuted as a non-invasive blood glucose alert device at the CES Digital Health exhibit, with the company publicly documenting its path through FDA review toward a direct glucose-monitoring claim.
• FDA framework: breath-analyte devices claiming a diabetes-relevant diagnostic use require FDA 510(k) or De Novo review, with the bar significantly higher for a direct blood-glucose claim (PREEVNT’s ISAAC) than for a general metabolic/ketone wellness claim.

03CN#

No dedicated Chinese exhaled-breath glucose monitoring company cleared source confirmation as of 2026; Chinese coverage of non-invasive glucose monitoring in this period centers on the broader technology-trend market rather than a specific breath-based commercial originator.

market-trend coverage, NMPA pathway#

• Market-trend focus: Chinese industry reporting on non-invasive glucose monitoring covers the broader technology category (including optical and other non-breath approaches) rather than a dedicated breath-analyte company.
• NMPA pathway: any breath-based glucose or ketone monitoring device reaching Chinese clinical use would register with NMPA as a medical device, following a validation-heavy pathway given the category’s early clinical-evidence stage.

04EU#

No dedicated European exhaled-breath glucose monitoring originator cleared source confirmation as of 2026; the category’s confirmed commercial activity remains concentrated in the US.

IVDR pathway#

• IVDR framework: were a breath-based glucose or ketone monitoring device to enter the EU market, it would require conformity assessment and CE marking under the In Vitro Diagnostic Regulation (IVDR 2017/746), the same framework governing other point-of-care diagnostic devices in this catalog.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack applies solid-state gas-sensing chemistry to breath acetone and related volatile organic compounds, with the field’s leading edge now pushing toward a more direct blood-glucose correlate rather than the established ketone proxy.

1. Breath acetone/ketone gas sensing (Breath Acetone Ketone Sensing):
   • PranaQ, Invoy Technologies and LEVL all use electrochemical or semiconductor sensors tuned to detect breath acetone, a metabolic byproduct of fat oxidation that rises during ketosis and carries diabetes-relevant risk information for ketoacidosis monitoring.
2. Wearable breath-analyte hardware (Wearable Breath Analyte Measurement):
   • Invoy Technologies’ patented wearable measurement device extends breath analysis beyond a single handheld reading toward more frequent or continuous sampling.
3. Direct blood-glucose breath correlate (Breath Glucose Alert Devices):
   • PREEVNT’s ISAAC device pursues a technical approach aimed at a more direct blood-glucose alert claim, distinguishing it from the acetone/ketone-proxy devices that currently anchor the category’s commercial base.
4. Regulatory validation pathway (FDA Clearance Pathway):
   • PREEVNT has publicly documented ISAAC’s path through FDA review, illustrating the clinical-validation bar every device in this category must clear before its specific glucose or ketone claim can be marketed as a diagnostic rather than a wellness product.

07Value chains and production pipelines#

Industrial pipeline of an exhaled-breath glucose/ketone monitor (FDA 510(k)/De Novo / EU IVDR 2017/746)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Breath sample          │ ───> │ 2. Gas sensor detection   │
│    collection                │      │                           │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Alert/reading           │ <─── │ 3. Signal processing &   │
│    generation                │      │    calibration               │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Regulatory clearance   │ ───> │ 6. Diabetes management    │
│                            │      │    integration               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Breath sample collection

The user exhales into a handheld or wearable device, a non-invasive procedure requiring no blood draw and taking only seconds.

Stage 2: Gas sensor detection

An electrochemical or semiconductor gas sensor detects the target analyte — breath acetone for PranaQ, Invoy Technologies and LEVL, or PREEVNT’s targeted glucose-correlate signal — at the trace concentrations present in exhaled breath.

Stage 3: Signal processing and calibration

The raw sensor signal is processed and calibrated against a validated blood-reference measurement (blood ketone or blood glucose), the step where each device’s accuracy claim is established during clinical validation.

Stage 4: Alert and reading generation

The device outputs a reading or alert to the user’s app — an elevated-ketone warning relevant to diabetic ketoacidosis risk, or, for PREEVNT’s ISAAC, a glucose-trend alert.

Stage 5: Regulatory clearance

The device undergoes FDA 510(k) or De Novo review, or EU IVDR conformity assessment, with a direct blood-glucose claim (ISAAC) facing a substantially higher evidentiary bar than a general ketone/metabolic wellness claim.

Stage 6: Diabetes management integration

The reading informs diet, insulin dosing or ketoacidosis-risk management decisions, used alongside — not yet as a replacement for — standard fingerstick or continuous glucose monitoring.